| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
|
| [2] |
Shibata A, Matsuda T, Ajiki W, et al. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001[J]. Jpn J Clin Oncol, 2008, 38(7): 464-8.
|
| [3] |
Shimada H, Shiratori T, Okaumi S, et al. Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience[J]. J Am Coll Surg, 2008, 206(1): 48-56.
|
| [4] |
Zhang J, Xie X, Ye DF. Adhesion molecule and tumor immune escape[J]. Shi Yong Zhong Liu Za Zhi, 2004,19(5):449-52.[ ,л ,Ҷ . * [J]. ʵ ־,2004, 19(5):449-52.]
|
| [5] |
Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infections and autoimmune diseases[J]. N Engl J Med, 1996,335(18):1369-77.
|
| [6] |
Li YJ, Dong WL The last advances of study on the B7 family members[J].Guo Ji Mian Yi Xue Za Zhi, 2011, 34(3): 221-6.[ , . B7 Ա о ½ չ[J]. ѧ ־, 20 11, 34(3): 221-6.]
|
| [7] |
Wang SD, Chen LP. The immunoregulatory function of B7-CD28 family[J]. Shanghai Mian Yi Xue Za Zhi, 2003,23(1):1-5.[ ʢ , ƽ. B7-CD28 ӵ ߵ ڹ [J]. Ϻ ѧ ־, 2003, 23(1):1-5.]
|
| [8] |
Luo YP, Chen SR, Yang W. The expressions of CD80 and CD86 in the tissues of esophageal carcinoma[J]. Hainan Yi Xue Yuan Xue Bao, 2006, 12(3):204-6.[ ƽ, , ΰ. CD80 CD86 ʳ ܰ ֯ еı [J]. ҽѧԺѧ , 2006, 12(3): 204-6.]
|
| [9] |
Chen CY, Zhu HT, Guo JY, et a1. Construction, expression and biological function assay of anti-human CD80 bivalent dimer[J]. Xian Dai MianYi Xue, 2011, 31(3):192-6.[ ² , 컪ͤ, , . CD80˫ ۿ Ĺ Ｐ ѧ ܳ [J] ִ ѧ, 2011, 31(3):192-6.]
|
| [10] |
Wang YR, Ma HB, Chen YJ, et a1.Inhibitory and lethal effects of human-mouse chimeric antibody against CD80 on the growth of B lymphoma cell lines Raji and Daudi[J].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2009, 25(7):615-8.[ , , , ȣ CD80 - Ƕ Ͽ B ܰ ϸ Raji Daudi ɱ [J].ϸ ѧ ־, 2009,25(7):615-8.]
|
| [11] |
Zhang X, Mei W, Zhang L, et a1 Co-expression of P1A35-43/ beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model[J].Oncol Rep, 2009, 22(5):1213-20.
|
| [12] |
Boussiotis VA, Freeman GJ, Grlbben JG, et a1 The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response[J]. Immunol Rev, 1996,153: 5-26.
|
| [13] |
Lu J, Zhao J, Song Q, et a1.Combination effect of human B7-2 and dentric cells vaccines in anti-esophageal cancer in vitro[J]. Shijie Hua Ren Xiao Hua Za Zhi, 2005,13(12):1382-5.[· , , ǫ, . B7-2 DC յ ʳ ܰ [J] 绪 ־, 2005, 13(12):1382-5.]
|
| [14] |
Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion[J]. Cancer Immunol Immunother, 20 07, 56(5): 739-45.
|
| [15] |
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol, 20 01, 2(3): 261-8.
|
| [16] |
Li H, Ren XB. New members of B7 family-B7-H1, B7-H2, B7-H3 and B7-DC[J].Guo Wai Yi Xue (Mian Yi Xue Fen Ce), 2005, 28 (1):41-3.[ , 㱦. B7 ³ Ա-B7-H1 B7-H2 B7-H3 B7-DC[J]. ҽѧ( ѧ ֲ ), 2005, 28(1):41-3.]
|
| [17] |
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(9):793-800.
|
| [18] |
Meng Q, Liu SM, Wang YL, et al. Effects of HG Keli on GSH,MDA and TNF-α of HF model rats induced by Carbon Tetrar-chloride compounded other factors[J]. Zhengzhou Da Xue Xue Bao(Yi Xue Ban), 2009, 44(1):48-51.[ , , һ , . ʳ ״ϸ ֯ B7-H1 mRNA ı [J]. ֣ ݴ ѧѧ ҽѧ 棩, 2009,44(1):48-51.]
|
| [19] |
Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis[J]. J Immunol, 2002,169(7):3581-8.
|
| [20] |
Liu SM, Liu ZJ. Expression of B7-H1 in esophageal carcinoma and its impact on T cell function [C]// Proceedings of the 6th Chinese national immunology conference. Xi,an:China Society for Immunnology,2008:201-2.[ , ռ . B7-H1 ʳ ܰ ֯ ı Ｐ Tϸ ߹ ܵ Ӱ [C]// ȫ ѧ ѧ Ļ . : й ѧ ,2008:201-2.]
|
| [21] |
Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity[J]. Immunity, 2003, 18 (6): 849-61.
|
| [22] |
Prasad DV,Richards S,Mai XM,et al.B7S1,a novel B7 family member that negatively regulates T cell activation[J].Immunity, 20 03,18(6):863-73.
|
| [23] |
Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity[J].J Immunother,2007,30(3):251-60.
|
| [24] |
Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma[J]. Cancer Res,2007, 67(18):8900-5.
|
| [25] |
Chen LJ, Sun J, Wu HY, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma[J].Cancer Immunol Immunother, 2011, 60 (7) : 1047-55
|
| [26] |
Lu B,Chen L,Liu L,et al.T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract[J].Immunol Res,2011,50(2-3): 269-75
|
| [27] |
Wang X, Hao J, Metzger DL, et al.B7-H4 treatment of T cells inhibits ERK,JNK,p38,and AKT activation[J].PLoS One, 2012, 7 (1) : e28232
|
下载:
